OVACE PLUS- sulfacetamide sodium liquid United States - English - NLM (National Library of Medicine)

ovace plus- sulfacetamide sodium liquid

mission pharmacal company - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

OVACE PLUS- sodium sulfacetamide liquid United States - English - NLM (National Library of Medicine)

ovace plus- sodium sulfacetamide liquid

mission pharmacal company - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

AVAR LS- sulfacetamide sodium, sulfur emulsion United States - English - NLM (National Library of Medicine)

avar ls- sulfacetamide sodium, sulfur emulsion

mission pharmacal company - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

AVAR LS- sodium sulfacetamide, sulfur aerosol, foam United States - English - NLM (National Library of Medicine)

avar ls- sodium sulfacetamide, sulfur aerosol, foam

mission pharmacal company - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease. general: nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. although rare, sensitivity to sodium sulfacetamide may occur. therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. if the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. patients should be carefully observed for possible local irritation or sensitization during long-term therapy. systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hyp

AVAR LS CLEANSING PADS- sulfacetamide sodium, sulfur cloth United States - English - NLM (National Library of Medicine)

avar ls cleansing pads- sulfacetamide sodium, sulfur cloth

mission pharmacal company - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

FUROSEMIDE tablet United States - English - NLM (National Library of Medicine)

furosemide tablet

blenheim pharmacal, inc. - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - furosemide 20 mg - furosemide tablets, usp is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. furosemide is particularly useful when an agent with greater diuretic potential is desired. furosemide tablets, usp may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.

BINOSTO- alendronate sodium tablet, effervescent United States - English - NLM (National Library of Medicine)

binosto- alendronate sodium tablet, effervescent

mission pharmacal company - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 70 mg - binosto effervescent tablet 70 mg is indicated for the treatment of osteoporosis in postmenopausal women. for the treatment of osteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies ( 14.1).] binosto is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies ( 14.2)] . the optimal duration of use has not been determined. the safety and effectiveness of binosto for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. binosto i

OVACEPLUS PLUS- sulfacetamide sodium cream United States - English - NLM (National Library of Medicine)

ovaceplus plus- sulfacetamide sodium cream

mission pharmacal company - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 g - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

OVACE PLUS- sulfacetamide sodium lotion United States - English - NLM (National Library of Medicine)

ovace plus- sulfacetamide sodium lotion

mission pharmacal company - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 98 mg in 1 g - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

AVAR- sodium sulfacetamide, sulfur aerosol, foam United States - English - NLM (National Library of Medicine)

avar- sodium sulfacetamide, sulfur aerosol, foam

mission pharmacal company - sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfur 50 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease. general: nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. although rare, sensitivity to sodium sulfacetamide may occur. therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. if the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. patients should be carefully observed for possible local irritation or sensitization during long-term therapy. systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hyp